Deal Snapshot
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Monday 22 November 2021

US- and China-based biopharmaceutical company Zenas BioPharma has acquired from US-based biopharmaceutical company Xencor, Inc. (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab, the companies said.

Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain and uses Xencor's XmAb Immune Inhibitor Fc Domain to target Fc?RIIb, a receptor that inhibits the function of B-cells, which are important components in the immune system.

Date Published: 22/11/2021